Multivariable analysis evaluating the association between CDAI components at baseline and persistent depression, controlling for other significant baseline variables.
| CDAI Components at Enrolment | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|
| SJC28 | 1.03 (0.99–1.07) | 1.07 (1.01–1.12) |
| TJC28 | 1.06 (1.03–1.09) | 1.14 (1.01–1.28) |
| PtGA | 1.19 (1.09–1.31) | – |
| PGA | 1.11 (1.00–1.22) | – |
| Female sex | 2.16 (1.24–3.76) | 3.67 (1.78–7.60) |
| HAQ-DI | 2.05 (1.51–2.79) | – |
| HAQ pain index | 1.63 (1.24–2.10) | – |
| Fatigue score | 1.18 (1.10–1.28) | – |
| No. comorbidities | 1.59 (1.42–1.78) | 1.41 (1.25–1.60) |
| RF-positive | 0.59 (0.37–0.92) | – |
| Prior use of csDMARD | 0.52 (0.33–0.81) | 0.41 (0.23–0.72) |
| Prior use of bDMARD | 0.43 (0.19–0.98) | – |
| Current use of bDMARD | 2.38 (1.11–5.12) | – |
| Fatigue score | 1.18 (1.10–1.28) | – |
Values in bold face are statistically significant. CDAI: Clinical Disease Activity Index; SJC28: 28-joint swollen joint count; TJC28: 28-joint tender joint count; PtGA: patient’s global assessment; PGA: physician’s global assessment; HAQ-DI: Health Assessment Questionnaire–Disability Index; RF: rheumatoid factor; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD.